EUVIMEDEUVIMED entdecken
Crossref

Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy

Nathaniel Deboever, Erin M Bayley, Michael A Eisenberg, Wayne L Hofstetter, Reza J Mehran, David C Rice, Ravi Rajaram, Jack A Roth, Boris Sepesi, Stephen G Swisher, Ara A Vaporciyan, Garrett L Walsh und 3 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2024-03 · 167 (3) · 814-819.e2

DOI: 10.1016/j.jtcvs.2023.07.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024-03. Verfasst von Nathaniel Deboever und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex. Hauptthemen laut MEDLINE: Metastasectomy, Lung Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Appropriately selected patients clearly benefit from resection of colorectal cancer (CRC) pulmonary metastases (PMs). However, there remains equipoise surrounding optimal chest surveillance strategies following pulmonary metastasectomy. We aimed to identify risk factors that may inform chest surveillance in this population. METHODS: Patients who underwent CRC pulmonary metastasectomy were identified from a single institution's prospectively maintained surgical database. Clinicopathologic and genomic characteristics were collected. Patients were stratified by diagnosis of subsequent PM within 6 months of the index lung resection. Multivariate modeling was used to evaluate risk factors. RESULTS: A total of 197 patients met the study's inclusion criteria, of whom 52.3% (n = 103) developed subsequent PM, at a median of 9.51 months following the index metastasectomy. Patients with KRAS alterations (odds ratio [OR], 3.073; 95% confidence interval [CI], 1.363-6.926; P = .007), TP53 alterations (OR, 3.109; 95% CI, 1.318-7.341; P = .010) were found to be at risk of PM diagnosis within 6 months of the index metastasectomy, while those with an APC alteration (OR, .218; 95% CI, 0.080-0.598; P = .003) were protected. Moreover, patients who received systemic therapy within 3 months of the initial PM diagnosis also were more likely to develop early lung recurrence (OR, 2.105; 95% CI, 0.971-4.563; P = .059). CONCLUSIONS: Patients with KRAS alterations, TP53 alterations, and no APC alterations developed early recurrence in the lung following pulmonary metastasectomy, as did those who received chemotherapy after their initial PM diagnosis. As such, these groups benefit from early lung imaging after metastasectomy, as chest surveillance protocols should be based on patient-centered clinicopathologic and genomic risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetastasectomyLung NeoplasmsColorectal NeoplasmsHumansProto-Oncogene Proteins p21(ras)PneumonectomyLungRisk FactorsPrognosisSurvival RateRetrospective Studies

Stichwörter der Autor:innen

chest surveillancecolorectal pulmonary metastasispulmonary metastasectomy

Substanzen

Proto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Department of General Surgery, Baylor University, Houston, Tex.
  • Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex. Electronic address: MBAntonoff@MDAnderson.org.

Zitieren

APA

Deboever, N., Bayley, E. M., Eisenberg, M. A., Hofstetter, W. L., Mehran, R. J., Rice, D. C., Rajaram, R., Roth, J. A., Sepesi, B., Swisher, S. G., Vaporciyan, A. A., Walsh, G. L., Bednarski, B. K., Morris, V. K., & Antonoff, M. B. (2024). Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. The Journal of Thoracic and Cardiovascular Surgery, 167(3), 814-819.e2. https://doi.org/10.1016/j.jtcvs.2023.07.017

Vancouver

Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, et al. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. The Journal of Thoracic and Cardiovascular Surgery. 2024;167(3):814-819.e2. doi:10.1016/j.jtcvs.2023.07.017

BibTeX
@article{Deboever2024,
  author = {Deboever, Nathaniel and Bayley, Erin M and Eisenberg, Michael A and Hofstetter, Wayne L and Mehran, Reza J and Rice, David C and Rajaram, Ravi and Roth, Jack A and Sepesi, Boris and Swisher, Stephen G and Vaporciyan, Ara A and Walsh, Garrett L and Bednarski, Brian K and Morris, Van K and Antonoff, Mara B},
  title = {Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2024},
  volume = {167},
  number = {3},
  pages = {814--819.e2},
  doi = {10.1016/j.jtcvs.2023.07.017}
}
Kostenlos starten →